Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules.
Flawless balance sheet with high growth potential.
Share Price & News
How has Co-Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CODX's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CODX exceeded the US Medical Equipment industry which returned 15.5% over the past year.
Return vs Market: CODX exceeded the US Market which returned 16.3% over the past year.
Price Volatility Vs. Market
How volatile is Co-Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StHere's Why We're Not At All Concerned With Co-Diagnostics's (NASDAQ:CODX) Cash Burn Situation
3 months ago | Simply Wall StHow Important Was Sentiment In Driving Co-Diagnostics' (NASDAQ:CODX) Fantastic 1219% Share Price Gain?
4 months ago | Simply Wall StCo-Diagnostics, Inc. (NASDAQ:CODX): Are Analysts Optimistic?
Is Co-Diagnostics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CODX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CODX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CODX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CODX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CODX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CODX is overvalued based on its PB Ratio (36.9x) compared to the US Medical Equipment industry average (3.9x).
How is Co-Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CODX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: CODX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CODX's is expected to become profitable in the next 3 years.
Revenue vs Market: CODX's revenue (25.1% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: CODX's revenue (25.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CODX's Return on Equity is forecast to be high in 3 years time
How has Co-Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CODX is currently unprofitable.
Growing Profit Margin: CODX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CODX is unprofitable, and losses have increased over the past 5 years at a rate of 24.8% per year.
Accelerating Growth: Unable to compare CODX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CODX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).
Return on Equity
High ROE: CODX has a negative Return on Equity (-30.74%), as it is currently unprofitable.
How is Co-Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: CODX's short term assets ($19.6M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: CODX's short term assets ($19.6M) exceed its long term liabilities ($120.0K).
Debt to Equity History and Analysis
Debt Level: CODX is debt free.
Reducing Debt: CODX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CODX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CODX has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 32.3% each year.
What is Co-Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CODX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CODX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CODX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CODX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CODX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dwight Egan (67 yo)
Mr. Dwight H. Egan serves as the Chairman, Chief Executive Officer and President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan serves as President, Chief Executive Officer an ...
CEO Compensation Analysis
Compensation vs Market: Dwight's total compensation ($USD460.00K) is below average for companies of similar size in the US market ($USD3.02M).
Compensation vs Earnings: Dwight's compensation has been consistent with company performance over the past year.
|Chairman||no data||US$460.00k||no data|
|Independent Director||3.25yrs||US$72.75k||no data|
|Independent Director||1yr||US$45.83k||0.091% |
|Independent Director||1.17yrs||US$45.25k||no data|
|Independent Director||1.17yrs||US$29.75k||0.091% |
Experienced Board: CODX's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CODX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.4%.
Co-Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Co-Diagnostics, Inc.
- Ticker: CODX
- Exchange: NasdaqCM
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$706.472m
- Shares outstanding: 27.46m
- Website: https://www.codiagnostics.com
Number of Employees
- Co-Diagnostics, Inc.
- 2401 South Foothill Drive
- Suite D
- Salt Lake City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CODX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jul 2017|
|C97||MUN (Boerse Muenchen)||Yes||Common Stock||DE||EUR||Jul 2017|
|C97||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2017|
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/09 23:32|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.